サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1630989

硬化療法の世界市場：市場規模・シェア・動向分析 (薬剤別・種類別・用途別・地域別・セグメント別、2025年～2030年)

Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
硬化療法の世界市場：市場規模・シェア・動向分析 (薬剤別・種類別・用途別・地域別・セグメント別、2025年～2030年)
出版日: 2024年12月05日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

硬化療法市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の硬化療法の市場規模は2025年から2030年にかけてCAGR 4.4%で拡大し、2030年には15億米ドルに達すると推定されています。

硬化療法は、網目状静脈、下肢毛細血管拡張症、静脈瘤の一次治療として広く使用されている非侵襲的な手順です。手順では、そのような痛み、ほてり、腫れ、けいれんなどの関連する症状の治療を支援し、それらを縮小させ、最終的に消え、影響を受けた静脈に直接溶液 (硬化剤) を注入することから構成されています。適用部位へのより良い暴露、侵襲性の低い技術の利用、皮膚科学の進歩、および静脈瘤の発生率と増加する高齢者人口のような要因は、市場の成長を煽っています。

静脈瘤の治療に使用される硬化剤は、洗浄剤、高浸透圧剤/浸透圧剤、および化学刺激剤に分類されます。テトラデシル硫酸ナトリウム (Sotradecol) およびポリドカノール (Asclera)、モルヒ酸ナトリウム (Scleromate)、オレイン酸エタノールアミン (Ethamoline) のような薬剤はすべて、静脈損傷の治療と影響を軽減するために使用されるFDA承認硬化剤です。血管外科学会によると、先進国では女性の33.0%以上、男性の約17.0%が毛細血管拡張症や静脈瘤のために医師に相談しており、米国だけでも35.0%の人々に影響を及ぼしています。

この状態を放置すると、慢性疼痛、深部静脈血栓、皮膚潰瘍、冠動脈疾患などの深刻な健康問題を引き起こす可能性があります。NCBIによると、全成人の20.0%が人生のある時点で静脈瘤にかかるとされ、その有病率は高齢化社会と女性の間でより高いです。これらの要因が市場の成長を押し上げると予想されます。しかし、一部の患者では色素沈着や艶消し、瘢痕化、アレルギー反応など、この処置の副作用が市場成長の妨げになる可能性があります。

硬化療法市場：分析概要

  • 洗浄剤セグメントは、FDAによる高い承認、血栓形成のリスクの低さ、有効性、医師の間での人気のため、2024年の収益シェア43.5%で市場を独占しました。
  • 発泡硬化療法セグメントは、液体硬化療法よりも現場への露出度が高く、結果も良いため、予測期間中に急成長すると予想されます。
  • 北米の硬化療法市場は、新しい技術に対する需要の増加、主要プレイヤーの大規模なプール、静脈瘤の有病率の上昇、および地域の高度な医療インフラに起因し、2024年に44.5%の売上高シェアで世界を支配しました。
  • アジア太平洋の硬化療法市場は、予測期間中に5.7%の最高のCAGRを記録すると予想されます。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 硬化療法市場：変動要因・傾向・範囲

  • 市場連関の見通し
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因の分析
  • ビジネス環境分析
    • 業界分析：ポーターのファイブフォース分析
    • PESTLE分析

第4章 硬化療法市場：薬剤別のビジネス分析

  • 市場シェア：薬剤別 (2024年・2030年)
  • セグメントダッシュボード：薬剤別
  • 市場規模の予測と動向分析：薬剤別 (2018～2030年)
  • 洗剤
  • 化学刺激物
  • 浸透圧剤

第5章 硬化療法市場：種類別のビジネス分析

  • 市場シェア：種類別 (2024年・2030年)
  • セグメントダッシュボード：種類別
  • 市場規模の予測と動向分析：種類別 (2018～2030年)
  • 超音波硬化療法
  • 液体硬化療法
  • フォーム硬化療法

第6章 硬化療法市場：用途別のビジネス分析

  • 市場シェア：用途別 (2024年・2030年)
  • セグメントダッシュボード：用途別
  • 市場規模の予測と動向分析：用途別 (2018～2030年)
  • 静脈瘤
  • リンパ管の奇形
  • 痔
  • 水腫

第7章 硬化療法市場：地域別の推定・動向分析

  • 市場シェア：地域別 (2024年・2030年)
  • 市場ダッシュボード：地域別
  • 市場規模の予測と動向分析 (2018～2030年)
  • 北米
    • 国別 (2018～2030年)
    • 米国
    • カナダ
  • 欧州
    • 国別 (2018～2030年)
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • デンマーク
    • スウェーデン
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • 韓国
    • オーストラリア
    • タイ
  • ラテンアメリカ
    • 国別 (2018～2030年)
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • 国別 (2018～2030年)
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第8章 競合情勢

  • 市場参入企業：概要
  • 企業の市場ポジション分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • LGM Pharma
    • Troikaa
    • Viatris Inc.
    • Omega Pharmaceuticals Pvt. Ltd.
    • Merz Pharma
    • ENDO-FLEX GmbH.
    • Perrigo Company plc
    • Medi-Globe GmbH
    • Medtronic
    • AngioDynamics
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global sclerotherapy market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 5 Global sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 6 Global sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 7 North America sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 9 North America sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 10 North America sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 11 U.S. sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 12 U.S. sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 14 Canada sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 15 Canada sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 16 Canada sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 17 Europe sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 18 Europe sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 19 Europe sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 20 Europe sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 21 UK sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 22 UK sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 23 UK sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Germany sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 25 Germany sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 26 Germany sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 27 France sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 28 France sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 29 France sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 30 Italy sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 31 Italy sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 32 Italy sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 33 Spain sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 34 Spain sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Spain sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 36 Norway sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 37 Norway sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Norway sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 39 Denmark sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 40 Denmark sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Denmark sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 42 Sweden sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 43 Sweden sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 44 Sweden sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 45 Asia Pacific sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 46 Asia Pacific sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 47 Asia Pacific sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 48 Asia Pacific sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 49 Japan sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 50 Japan sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 51 Japan sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 52 China sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 53 China sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 54 China sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 55 India sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 56 India sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 57 India sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 58 Australia sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 59 Australia sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 60 Australia sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 61 South Korea sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 62 South Korea sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 63 South Korea sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 64 Thailand sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 65 Thailand sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 66 Thailand sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 67 Latin America sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 68 Latin America sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 69 Latin America sclerotherapy market, by type, 2018 - 2030 (USD Billion
  • Table 70 Latin America sclerotherapy market, by application, 2018 - 2030 (USD Billion
  • Table 71 Brazil sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 72 Brazil sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Brazil sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 74 Mexico sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 75 Mexico sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Mexico sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 77 Argentina sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 78 Argentina sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Argentina sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 80 Middle East & Africa sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 81 Middle East & Africa sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 82 Middle East & Africa sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Middle East & Africa sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 84 South Africa sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 85 South Africa sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 86 South Africa sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 87 Saudi Arabia sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 88 Saudi Arabia sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Saudi Arabia sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 90 UAE sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 91 UAE sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 92 UAE sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 93 Kuwait sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 94 Kuwait sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 95 Kuwait sclerotherapy market, by application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Sclerotherapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Agents outlook (USD Billion)
  • Fig. 10 Type outlook (USD Billion)
  • Fig. 11 Application outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Sclerotherapy market dynamics
  • Fig. 14 Sclerotherapy market: Porter's five forces analysis
  • Fig. 15 Sclerotherapy market: PESTLE analysis
  • Fig. 16 Sclerotherapy market: Agents segment dashboard
  • Fig. 17 Sclerotherapy market: Agents market share analysis, 2024 & 2030
  • Fig. 18 Detergents market, 2018 - 2030 (USD Billion)
  • Fig. 19 Chemical irritants market, 2018 - 2030 (USD Billion)
  • Fig. 20 Osmotic agents market, 2018 - 2030 (USD Billion)
  • Fig. 21 Sclerotherapy market: Type segment dashboard
  • Fig. 22 Sclerotherapy market: Type market share analysis, 2024 & 2030
  • Fig. 23 Ultrasound sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 24 Liquid sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 25 Foam sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 26 Sclerotherapy market: Application segment dashboard
  • Fig. 27 Sclerotherapy market: Application market share analysis, 2024 & 2030
  • Fig. 28 Varicose veins market, 2018 - 2030 (USD Billion)
  • Fig. 29 Malformed lymph vessels market, 2018 - 2030 (USD Billion)
  • Fig. 30 Hemorrhoids market, 2018 - 2030 (USD Billion)
  • Fig. 31 Hydroceles market, 2018 - 2030 (USD Billion)
  • Fig. 32 Sclerotherapy market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 39 Europe sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 44 France country dynamics
  • Fig. 45 France sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark sclerotherapy market, 2018 - 2030 (USD Billion
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 56 Asia Pacific sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 59 China country dynamics
  • Fig. 60 China sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 61 India country dynamics
  • Fig. 62 India sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 69 Latin America sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 72 Mexico country dynamics
  • Fig. 73 Mexico sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 76 MEA sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework
目次
Product Code: GVR-4-68039-010-4

Sclerotherapy Market Growth & Trends:

The global sclerotherapy market size is estimated to reach USD 1.50 billion by 2030, expanding at a CAGR of 4.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sclerotherapy is a non-invasive procedure that is widely used as a primary treatment for reticular veins, leg telangiectasias, and varicose veins. The procedure comprises injecting a solution (sclerosing agents or sclerosants) straight into the affected veins, which causes them to shrink and eventually disappear and assist in treating related symptoms such as aching, burning, swelling, and cramping. Factors like the better exposure to the site of application, utilization of less-invasive technologies, advances in dermatology, and increasing geriatric population with an incidence of varicose veins are fuelling the market growth.

Sclerosing agents used for the treatment of varicose veins are segmented into detergents, hyperosmolar/ osmotic agents, and chemical irritants. Agents like Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Sodium morrhuate (Scleromate), Ethanolamine Oleate (Ethamoline) are all FDA approved sclerosants used to treat and reduce the effect of vein damage. According to the Society of Vascular surgery, more than 33.0% of women and about 17.0% of men consult a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the U.S. alone.

This condition, if left untreated can cause severe health problems such as chronic pain, deep vein clots, skin ulcers, and coronary ailments. According to NCBI, 20.0% of all adults will get varicose veins at some point in their lives and the prevalence is higher among the aging population and women. These factors are expected to boost the market growth. However, the side effects of this procedure such as hyperpigmentation and matting, scarring, and allergic reactions in some patients might hinder the market growth.

Sclerotherapy Market Report Highlights:

  • The detergents segment dominated the market with a revenue share of 43.5% in 2024 owing to high approvals by the FDA, low risk of clot formation, effectiveness, and its popularity among doctors
  • The foam sclerotherapy segment is anticipated to grow fast over the forecast period due to better exposure to the onsite and results than liquid sclerotherapy
  • North America sclerotherapy market dominated the global with a revenue share of 44.5% in 2024 owing to increasing demand for new technologies, a large pool of key players, rising prevalence of varicose veins, and advanced healthcare infrastructure in the region
  • Asia Pacific sclerotherapy market is expected to register the highest CAGR of 5.7% over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Agents
    • 1.2.2. Type
    • 1.2.3. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Sclerotherapy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Sclerotherapy Market: Agents Business Analysis

  • 4.1. Agents Market Share, 2024 & 2030
  • 4.2. Agents Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Agents, 2018 to 2030 (USD Billion)
  • 4.4. Detergents
    • 4.4.1. Detergents Market, 2018 - 2030 (USD Billion)
  • 4.5. Chemical Irritants
    • 4.5.1. Chemical Irritants Market, 2018 - 2030 (USD Billion)
  • 4.6. Osmotic Agents
    • 4.6.1. Osmotic Agents Market, 2018 - 2030 (USD Billion)

Chapter 5. Sclerotherapy Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 5.4. Ultrasound Sclerotherapy
    • 5.4.1. Ultrasound Sclerotherapy Market, 2018 - 2030 (USD Billion)
  • 5.5. Liquid Sclerotherapy
    • 5.5.1. Liquid Sclerotherapy Market, 2018 - 2030 (USD Billion)
  • 5.6. Foam Sclerotherapy
    • 5.6.1. Foam Sclerotherapy Market, 2018 - 2030 (USD Billion)

Chapter 6. Sclerotherapy Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Billion)
  • 6.4. Varicose Veins
    • 6.4.1. Varicose Veins Market, 2018 - 2030 (USD Billion)
  • 6.5. Malformed Lymph Vessels
    • 6.5.1. Malformed Lymph Vessels Market, 2018 - 2030 (USD Billion)
  • 6.6. Hemorrhoids
    • 6.6.1. Hemorrhoids Market, 2018 - 2030 (USD Billion)
  • 6.7. Hydroceles
    • 6.7.1. Hydroceles Market, 2018 - 2030 (USD Billion)

Chapter 7. Sclerotherapy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Mexico Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Regulatory Framework
      • 7.7.4.3. Competitive Insights
      • 7.7.4.4. Argentina Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. LGM Pharma
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Agents Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Troikaa
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Agents Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Viatris Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Agents Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Omega Pharmaceuticals Pvt. Ltd.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Agents Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merz Pharma
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Agents Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. ENDO-FLEX GmbH.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Agents Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Perrigo Company plc
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Agents Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Medi-Globe GmbH
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Agents Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Medtronic
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Agents Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. AngioDynamics
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Agents Benchmarking
      • 8.5.10.4. Strategic Initiatives